Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimegepant for intermittent prevention of menstrual migraine
NL-OMON58768Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Catamenial Migraine comparing Rimegepant with Placebo (2 arms). Primary endpoint: Mean change from the observation period in number of migraine days per 5-day perimenstrual period across each cycle of the double-blind treatment phase. Started Nov 2025; status: active, not recruiting.
02
Drugs
rimegepant
03
Conditions
Catamenial Migraine
Beyond the preview
Go deeper on NL-OMON58768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58768.